PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Lung Cancer (NSCLC), Lung Cancer (SCLC), Melanoma (Skin Cancer), Melanoma Metastatic. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
PD-L1 Targeting Peptide Probe 68Ga-cPP-BCH for PET Imaging of Solid Tumor
Overview
The objective of this study is to construct a noninvasive approach using radiolabbled peptide 68Ga-cPP-BCH PET/CT to detect the PD-L1 expression of tumor lesion in patients with lung cancer, melanoma and other solid tumor to identify patients benefiting from anti-PD-(L)1 treatment.
Primary outcome measures
- MPR [Time frame: 3-6 months]
Secondary outcome measures (1)
- ORR [Time frame: 3-6 months]
Eligibility criteria
Inclusion criteria
- Aged 18-75, male and female, with ECOG score of 0 or 1;
- Subjects with lung cancer, melanoma, or other solid tumors scheduled for immunotherapy or combined immunotherapy;
- underwent PD-L1 IHC examination before therapy;
- The expected survival was more than 26 weeks;
- Blood routine test, liver and kidney function meet the following standards: blood routine: WBC >= 4.0 x 10\^9/L or neutrophil >= 1.5 x 10\^9/:, PLT >= 100 x 10\^9 / L, Hb >= 90g / L; Pt or APTT <= 1.5 upper limit of normal value; liver and kidney function: total bilirubin <= 1.5 x ULT (upper limit of normal value), ALT / AST <= 2.5 upper limit of normal value or <= 5 x ULT (subject with liver metastasis), ALP <= 2.5 upper limit of normal value (if bone metastasis or liver metastasis exists, ALP <= 4.5 upper limit of normal value); BUN <= 1.5 x ULT, SCR <= 1.5 x ULT;
- According to RECIST1.1, there was at least one measurable target lesion;
- Understand and sign informed consent voluntarily with good compliance.
Exclusion criteria
- The function of liver and kidney was seriously abnormal;
- Preparation for pregnant, pregnant and lactating women;
- Inability to lie flat for half an hour;
- Suffering from claustrophobia or other mental disorders;
- Other researchers considered it unsuitable to participate in the trial.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07442292 · 2026KT10